Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1856 - Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Supportive Care and Symptom Management

Tumour Site


Nienke Lankheet


Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300


N.A..G. Lankheet1, K.R..M. Ferrier1, S.E. Gibbons2, D.M. Burger1, K. McAllister2, J.L..M. Martin2, S.H. Khoo2, N. van Erp1, F.G. Jansman3

Author affiliations

  • 1 Pharmacy, Radboud University Medical Centre Nijmegen, 6525 GA - Nijmegen/NL
  • 2 Molecular And Clinical Pharmacology, University of Liverpool, Liverpool/GB
  • 3 Clinical Pharmacy, Deventer Ziekenhuis, 7416 - Deventer/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1856


Patients with cancer are at risk to endure a drug-drug interaction (DDI) with their oncolytic drugs. To facilitate the safe prescription and use of oncolytics, the freely available website www.cancer-druginteractions.org was introduced. Hereby we present the results of the use of this online DDI resource since the launch in June 1st, 2017.


For the most frequently used co-medications (>400) in cancer patients DDI potential was reviewed based on registration documents and scientific literature. A simple “traffic light” system was used to warn for the interaction potential. Background information and level of evidence is provided in the summary for each interaction. Since the launch of the website the demographic use, the number of unique visitors and the number and severity of the interactions consulted are monitored every 3 months.


34 targeted oncolytics used for ten different malignancies have been added to the website. These represent 24 targeted oral oncolytics and 10 monoclonal antibodies (MoABs). Between June 1st, 2017 and March 31st, 2018 a total of 11,295 searches has been performed by 3,428 unique visitors from 35 countries. 78% of the searches were performed for oral oncolytics and 22% for MoABs. 20.8% of the searches showed a potential interaction which requires action of the prescriber. The table gives an overview of the searches performed. Frequently checked co-medications were for example coumarins, PPIs, dexamethasone, metamizole and aspirin. Currently, a user-friendly app is under development which will be launched in October 2018.Table: 1801P

Overview of DDI queries

Interaction classification ‘traffic light’ (%)
Green No clinically significant interaction63.3
Yellow Interaction of weak/moderate intensity; no a priori dosage adjustment required15.9
Amber Potential interaction which may require dosage adjustment or close monitoring14.3
Red Do not co-administer6.5
Countries consulted the website (%)
United Kingdom68
The Netherlands16
Other European countries (top 3: Spain, France, Switzerland)7
USA and Canada3
Asia-Pacific (top 3: Australia, India, Hong Kong)2


Thus far, the DDI checker is being used all over the world. More than 20% of the performed searches showed a clinically relevant interaction. The freely available website, and the soon to be launched app, will facilitate health care professionals’ awareness of potential DDIs between oncolytics and frequently used co-medications and this supports safe prescription.

Clinical trial identification

Legal entity responsible for the study

Radboudumc and University of Liverpool.


Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Ipsen, Janssen, Pfizer, Roche, Sanofi.

Editorial Acknowledgement


S.H. Khoo: Advisory board: Merck, ViiV; Corporate sponsored research: ViiV, Gilead, Merck, Janssen; Other: Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Gilead, Ipsen, Janssen, Pfizer, Roche, Sanofi. N. van Erp: Research funding: Novartis, Astellas, Janssen Cilag, AstraZeneca, GSK, Boehringer Ingelheim, Gilead, Roche, Pfizer, Sanofi. F.G. Jansman: Advisory board: Amgen, Servies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.